Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Neurocrine (NBIX) Stock Price & Analysis

1,674 Followers

NBIX Stock Chart & Stats

$166.05$1.20(0.73%)
At close: 4:00 PM EST
$140$150$160Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$162.02 - $169.02
52-Week Range
$122.14 - $186.12
Previous Close
$164.85
Volume
N/A
Average Volume (3M)
1.44M
Market Cap
$16.69B
Enterprise Value
$14.58B
Total Cash (Recent Filing)
$737.90M
Total Debt (Recent Filing)
$392.30M
Price to Earnings (P/E)
23.8
Beta
0.62
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
2.07
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Expansion

Strong revenue growth and improving net margins indicate that Neurocrine is scaling its commercial platform while converting more sales into earnings. The combination of high gross margins and rising profitability supports reinvestment in marketed products and pipeline development over the next several quarters.

Cash Generation And Low Leverage

Robust free cash flow that closely tracks net income gives Neurocrine substantial internal funding for research, commercialization, and capital returns. Very low leverage further preserves financial flexibility, reducing dependence on external financing while the company advances multiple clinical programs.

INGREZZA Commercial Durability

INGREZZA has a durable growth runway supported by continued prescription expansion, broad Medicare access, and a large undertreated patient population. Management expects volume growth to offset pricing pressure, while the expanded sales force should support adoption and reach across the next several quarters.

Bears Say

INGREZZA Pricing Pressure

Expected net pricing pressure creates a structural headwind for INGREZZA revenue quality and limits how much reported sales can benefit from prescription growth. Although management expects volume to offset concessions, sustained price erosion could constrain margin expansion and future earnings leverage.

VYKAT XR Commercial Execution

VYKAT XR remains an important growth opportunity, but delayed momentum and continued provider, patient, and caregiver education increase execution risk. Slower adoption or additional discontinuations could postpone the product's contribution to portfolio growth and require sustained commercial investment.

Pipeline Program Attrition

Discontinuing NBI-'986 narrows the development portfolio and removes one potential future contributor to diversification beyond current commercial products. While disciplined pruning can protect resources, repeated pipeline attrition would increase reliance on INGREZZA and the remaining clinical catalysts.

Neurocrine News

NBIX FAQ

What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $122.14 and its highest was $186.12 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $16.69B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 97 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Nov 02, 2026. The company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.05.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 2.07.
How many shares outstanding does Neurocrine have?
Neurocrine has 101,218,640 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.96 in its last earnings report, beating expectations of $1.91. Following the earnings report the stock price went up 13.416%.
Which hedge fund is a major shareholder of Neurocrine?
Hedge funds hold Neurocrine shares: the largest hedge-fund position in Neurocrine is 71,885,980 shares, and hedge funds decreased their holdings by 159.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology